Answers are grounded in this paper and cite their sources.
免疫性血小板减少症是儿童最常见的获得性免疫介导出血性疾病之一,其异质性明显,在儿童中尤其突出,具体发病机制、自然病程、并发症及治疗方案因人而异。随着免疫性血小板减少症(Immune Thrombocytopenic Purpura, ITP)在治疗的研究进展中,儿童ITP的治疗获得了一定突破,一般认为治疗儿童ITP的常见用药包括肾上腺糖皮质激素类药物、丙种球蛋白以及刺激血小板生成类药物等,新型药物以免疫抑制剂及生物制品等,本文探讨了国内外儿童免疫性血小板减少症的流行特征、发病机制及治疗进展,以此展开综述。 Immune thrombocytopenia is one of the most common acquired immune-mediated hemorrhagic diseases in children. Its heterogeneity is obvious, especially prominent in children. The specific pathogenesis, natural course, complications and treatment plan vary from person to person. As immune thrombocytopenia (ITP) in the diagnosis, treatment, the progress of the treatment of ITP in children to obtain a breakthrough, it is generally believed to treat common medication of ITP in children include sugar cortical hormone drugs, gamma globulin and stimulate platelet production drugs, new drugs to immunosuppressants and biological products, etc., This article will review the epidemiological characteristics, pathogenesis and treatment progress of immune thrombocytopenia in children at home and abroad.
No takes yet. Share an insight, caveat, or question.
登媛 岳 (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: